Julie Saiki reports a conversion at Azora Therapeutics
By AlphaYouPublished Form 4
Saiki Julie
Reporting filer
Julie Saiki reports a conversion, not an open-market purchase or sale, in Azora Therapeutics, Inc. (DE). Form 4 filed Nov 4, 2026 lists 2 entries.
- Disclosed
- Nov 4, 2026
Reported details
2 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Saiki Julie | 2026-11-02 | C | Conversion | 626252 | Not stated (see footnotes) | 761,636 | 2 days | Filed terms
|
| Series A Preferred Stock (derivative) | Saiki Julie | 2026-11-02 | C | Conversion | 626.252 | 0 | 1,225.977 | 2 days | Filed terms
|
Common Stock
- Owner
- Saiki Julie
- Date
- 2026-11-02
- Code
- C
- Action
- Conversion
- Quantity
- 626252
- Price
- Not stated (see footnotes)
- Following holdings
- 761,636
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: C
- equity Swap Involved: 0
- transaction Timeliness:
- transaction Shares: 626252
- id: F1
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 761636
- direct Or Indirect Ownership: D
Series A Preferred Stock (derivative)
- Owner
- Saiki Julie
- Date
- 2026-11-02
- Code
- C
- Action
- Conversion
- Quantity
- 626.252
- Price
- 0
- Following holdings
- 1,225.977
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Series A Preferred Stock
- id: F1
- transaction Date: 2026-11-02
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: C
- equity Swap Involved: 0
- transaction Timeliness:
- transaction Shares: 626.252
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: D
- id: F2
- id: F1
- underlying Security Title: Common Stock
- underlying Security Shares: 626252
- id: F1
- shares Owned Following Transaction: 1225.977
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Saiki Julie: Chief Strategy Officer.
- F1: Subject to certain beneficial ownership and other limits set forth in the Certificate of Designation of the Series A Preferred Stock, each share of Series A Preferred Stock converted into 1,000 shares of the Issuer's common stock and has no expiration date.
- F2: The Series A Preferred Stock converted automatically within three days of Issuer's stockholders approving a proposal for the issuance of Issuer common stock upon conversion of the Series A Preferred Stock pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer, Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer, and a private Delaware corporation that was then known as Azora Therapeutics, Inc.
Original sources
Prepared automatically from public filing data. Report a correction.